Group 1 - The stock price of Shangwei New Materials has significantly increased since July 2025, leading to abnormal trading fluctuations, and the company may apply for a trading suspension if the price continues to rise [1] - CITIC Securities reported a net profit of 30.05 billion yuan for 2025, a year-on-year increase of 38.46%, driven by growth in brokerage, investment banking, and proprietary trading [2] - Huibo Technology's controlling shareholder will change to Tianjin State-owned Assets Supervision and Administration Commission after transferring 341 million shares, representing 25.60% of the total share capital [3] Group 2 - Caixun Co. plans to issue convertible bonds to raise up to 1.46 billion yuan for projects including the construction of an intelligent computing center and AI application development [4] - Jinhaitong expects a net profit of 160 to 210 million yuan for 2025, a year-on-year increase of 103.87% to 167.58%, due to rising demand in the semiconductor packaging sector [5] - Aoyuan Ceiling announced that it may apply for a trading suspension if its stock price continues to rise significantly [6] Group 3 - Yanshan Technology's commercialization of brain-machine interface and brain-like intelligence business is still in the early stages, with no revenue generated yet [7] - Haige Communication expects a net loss for 2025 due to industry client adjustments and increased investment in innovative businesses [9] - Hu Silicon Industry anticipates a net loss of 1.28 to 1.53 billion yuan for 2025, with a significant increase in losses compared to the previous year [10] Group 4 - Guangyun Technology may apply for a trading suspension if its stock price continues to rise abnormally [11] - Wenkang Development plans to swap its main assets and liabilities with 100% equity of Wenkang Mining and Luzhong Mining, facilitating a business transformation [12] - Jinqiao Information clarified that its AI-related judicial business is not its main business and does not significantly impact overall performance [13] Group 5 - Yonghe Co. expects a net profit increase of 110.87% to 150.66% for 2025, while CITIC Bank anticipates a 2.98% increase in net profit to 70.62 billion yuan [14] - Guotou Power's power generation volume decreased by 8.12% year-on-year for 2025, while Jiamei Packaging expects a net profit decrease of 43% to 53% [14] - Shengke Communication anticipates a net loss of 120 to 160 million yuan for 2025 [14]

Core Viewpoint - Fosun Pharma (600196) is focusing on innovation and internationalization strategies while continuously monitoring cutting-edge technology trends and evaluating potential business opportunities based on market conditions, technological advancements, and the company's development plans [1] Group 1 - The company is actively engaging with investors through interactive platforms to address inquiries [1] - Fosun Pharma emphasizes the importance of aligning its strategies with market dynamics and technological progress [1] - The company is committed to exploring new business opportunities in relevant fields [1]

本报讯1月14日，据重药控股官方微信公众号消息，日前，重药控股参与投资的企业润生药业有限公司 （以下简称"润生药业"）申报的核心产品"沙美特罗替卡松吸入粉雾剂"（英文通用名：Fluticasone Propionate and Salmeterol Inhalation Powder USP，药品申请号：ANDA 214464）正式获得美国食品药品 监督管理局（FDA）批准上市。 此外，值得一提的是，重药控股透露，参股子公司重庆药友制药有限责任公司与上海复星医药产业发展 有限公司及辉瑞共同签订许可协议，就口服小分子胰高血糖素样肽-1受体（GLP-1R）激动剂（包括 YP05002）及含有该活性成分的产品授予辉瑞于许可区域（即全球范围）及领域（即人类、动物所有适 应症的治疗、诊断及预防）独家开发、使用、生产及商业化权利。截至目前，药友制药已收到辉瑞支付 的首付款15000万美元。 （文章来源：证券日报） 这是FDA首次批准中国药企自主研发的吸入粉雾剂（Dry Powder Inhaler，DPI），标志着中国高端复杂 制剂成功叩开国际主流市场大门。该产品以联合用药形式（支气管扩张剂与吸入糖皮质激素），用于可 逆 ...

Core Viewpoint - Fosun Pharma's subsidiary, Suzhou Er Ye Pharmaceutical, has recently had its drug registration application for injectable erythromycin lactobionate accepted by the National Medical Products Administration of China [1] Group 1: Drug Information - The drug is a chemical medication intended for use when oral administration is not feasible or when a rapid high serum concentration of erythromycin is required for treating infections caused by specific sensitive microbial strains [1] - It is also indicated for the prevention of initial rheumatic fever, recurrence of rheumatic fever, and bacterial endocarditis [1] Group 2: Financial and Market Data - As of December 2025, the cumulative R&D investment for this drug by the group is approximately RMB 6.33 million (unaudited) [1] - According to IQVIA CHPA data, the sales revenue for injectable erythromycin lactobionate in mainland China (excluding Hong Kong, Macau, and Taiwan) is projected to be around RMB 170 million in 2024 [1]

Core Viewpoint - A new private equity fund named Zhonghui Fuhong (Tianjin) Equity Investment Fund Partnership (Limited Partnership) has been established, focusing on equity investment, investment management, and asset management activities [1] Group 1: Fund Details - The fund has a total investment amount of 547 million yuan [1] - The executing partner is Hongyi Private Equity Fund Management (Tianjin) Partnership (Limited Partnership) [1] - The fund's partners include Zhonghui Life Insurance Co., Ltd., Shanghai Fosun Pharmaceutical Industry Development Co., Ltd., and Hongyi Private Equity Fund Management (Tianjin) Partnership (Limited Partnership) [1]

Group 1 - The core announcement is that Fosun Pharma's subsidiary, Suzhou Erye Pharmaceutical Co., Ltd., has had its drug registration application for injectable lactulose erythromycin accepted by the National Medical Products Administration [1] - The drug is intended for use when oral administration is not feasible or when a rapid high serum concentration of erythromycin is required for treating infections caused by specific sensitive microbial strains, as well as for preventing rheumatic fever and bacterial endocarditis [1] - As of December 2025, the cumulative R&D investment for this drug by the group is approximately RMB 6.33 million (unaudited) [1] Group 2 - According to the latest data from IQVIA CHPA, the sales revenue for injectable lactulose erythromycin in mainland China (excluding Hong Kong, Macau, and Taiwan) is projected to be approximately RMB 170 million in 2024 [1]

Core Viewpoint - Fosun Pharma's subsidiary, Suzhou Er Ye Pharmaceutical, has recently had its drug registration application for injectable lactulose erythromycin accepted by the National Medical Products Administration of China [1] Group 1: Drug Information - The drug is a chemical medication intended for use when oral administration is not feasible or when a rapid high serum concentration of erythromycin is required to treat infections caused by specific sensitive microbial strains [1] - It is also indicated for the prevention of initial rheumatic fever, recurrence of rheumatic fever, and bacterial endocarditis [1] Group 2: Financials and Market Potential - As of December 2025, the cumulative R&D investment for this drug by the group is approximately RMB 6.33 million (unaudited) [1] - According to the latest data from IQVIA CHPA, the sales revenue of injectable lactulose erythromycin in mainland China (excluding Hong Kong, Macau, and Taiwan) is projected to be around RMB 170 million in 2024 [1]

Group 1 - The core point of the article is that Fosun Pharma's subsidiary, Suzhou Er Ye Pharmaceutical Co., has recently had its drug registration application for injectable lactulose erythromycin accepted by the National Medical Products Administration of China [1] - The drug is intended for use in treating infections caused by specific microbial strains when oral administration is not feasible or when a rapid increase in serum erythromycin concentration is required [1] - The drug also aims to prevent the initial onset and recurrence of rheumatic fever, as well as to prevent bacterial endocarditis [1] Group 2 - As of December 2025, the cumulative R&D investment for this drug by the group is approximately RMB 6.33 million (unaudited) [1] - According to IQVIA CHPA data, the projected sales for injectable lactulose erythromycin in mainland China (excluding Hong Kong, Macau, and Taiwan) is approximately RMB 170 million in 2024 [1]

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責，對其準確性或完整性亦不 發表任何聲明，並明確表示，概不對因本公告全部或任何部份內容而產生或因倚賴該等內容而引致的任何損 失承擔任何責任。 上 海 復 星 醫 藥（ 集 團 ）股 份 有 限 公 司 Shanghai Fosun Pharmaceutical (Group) Co., Ltd.* （於中華人民共和國註冊成立的股份有限公司） （股份代號：02196） 海外監管公告 本公告乃根據香港聯合交易所有限公司證券上市規則第13.10B條而作出。 茲載列上海復星醫藥（集團）股份有限公司（「本公司」）在上海證券交易所網站刊登的《關於 參與設立之私募股權投資基金進展的公告》，僅供參閱。 承董事會命 上海復星醫藥（集團）股份有限公司 董事長 陳玉卿 中國，上海 2026 年1 月1 4 日 於本公告日期，本公司之執行董事為陳玉卿先生、關曉暉女士、文德鏞先生、王可心先生及劉毅先生；本公 司之非執行董事為陳啟宇先生及潘東輝先生；本公司之獨立非執行董事為余梓山先生、王全弟先生、Chen Penghui先生及楊玉成先生；以及本公司職工董事為嚴佳女士。 ...

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責，對其準確性或完整性亦不 發表任何聲明，並明確表示，概不對因本公告全部或任何部份內容而產生或因倚賴該等內容而引致的任何損 失承擔任何責任。 上 海 復 星 醫 藥（ 集 團 ）股 份 有 限 公 司 Shanghai Fosun Pharmaceutical (Group) Co., Ltd.* （於中華人民共和國註冊成立的股份有限公司） （股份代號：02196） 海外監管公告 中國，上海 2026 年1 月1 4 日 於本公告日期，本公司之執行董事為陳玉卿先生、關曉暉女士、文德鏞先生、王可心先生及劉毅先生；本公 司之非執行董事為陳啟宇先生及潘東輝先生；本公司之獨立非執行董事為余梓山先生、王全弟先生、Chen Penghui先生及楊玉成先生；以及本公司職工董事為嚴佳女士。 * 僅供識別 证券代码：600196 股票简称：复星医药 编号：临 2026-004 本公告乃根據香港聯合交易所有限公司證券上市規則第13.10B條而作出。 茲載列上海復星醫藥（集團）股份有限公司（「本公司」）在上海證券交易所網站刊登的《關於 控股子公司激勵計劃實施進展的 ...